Sharmila Joshi, head of equity at Peerless Securities told CNBC-TV18, “I would say exit Orchid Chemicals. We have a story where the numbers have been pretty bad. Today I think there has been some positive development because of which we are seeing a pullback, but overall within the pharma space, I would really avoid this stock.”
She further added, “If one is looking at midcap pharma, maybe on correction one can buy Ipca Laboratories.”Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
